Evidence map›Paper›PMID 41906847›Full record

ArticleJoint diseases and related surgery2026

Effects of soluble guanylate cyclase activator vericiguat on fracture healing in rats.

Azat Dzhumukov, Bilal Karabak, Aziz Demirci, Ferhat Yıldırım Hoyur, Muhammed Çağatay Engin

Abstract read
In one paragraph

Article in Joint diseases and related surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Azat Dzhumukov
Bilal Karabak
Aziz Demirci
Ferhat Yıldırım Hoyur
Muhammed Çağatay EnginAtatürk Üniversitesi Hastanesi, Ortopedi ve Travmatoloji Kliniği, 25040 Yakutiye, Erzurum, Türkiye. azat.dzhumukov@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to assess the healing effects of vericiguat at various concentrations on rat femur fractures through clinical and radiological and biomechanical and histopathological assessments. MATERIALS AND

methodsIn this study, a total of 60 female Wistar-Albino rats were used. The study comprised of six rat groups with 10 rats in each group: Group 1 (normal controls), Group 2 (positive controls - only fracture), Group 3 (low-dose vericiguat - 3 mg/kg), Group 4 (high-dose vericiguat - 6 mg/kg), Group 5 (fracture + low-dose vericiguat), Group 6 (fracture + high-dose vericiguat). Under general anesthesia, standard closed fractures were created in the right femurs of rats in the fracture groups. Radiological examinations were performed on Days 7, 14, and 28. The Lane-Sandhu scoring system was used for radiological assessment. At the end of Day 28, the rats were sacrificed, and the fracture healing tissues were examined biomechanically and histologically using the Huo scale.

resultsThe 28

conclusionOur study results suggest that soluble guanylate cyclase (sGC) activators show promise for fracture healing treatment when used at specific concentrations, but their therapeutic range remains limited and their toxic effects at high doses need careful consideration.

Indexed as

Enzyme ActivatorsFemoral FracturesFemurFracture HealingGuanylate CyclaseSoluble Guanylyl CyclaseAnimalsBiomechanical PhenomenaDisease Models, AnimalDose-Response Relationship, DrugFemaleRadiographyRatsRats, WistarEnzyme ActivatorsGuanylate CyclaseSoluble Guanylyl Cyclase

Identifiers

PMID41906847
PMCPMC13386387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.